{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:35:45Z","timestamp":1794663345087,"version":"4.9.1"},"posted":{"date-parts":[[2026,3,18]]},"group-title":"In Review","reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,17]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <bold>Introduction:<\/bold>\n                  South Africa was an early implementer of bedaquiline and linezolid for drug-resistant tuberculosis (TB), however, programmatic capacity for drug susceptibility testing (DST) was not initially available.\n                  <bold>Methods<\/bold>\n                  : We analysed people with rifampicin-resistant (RR)-TB (n=3138) programmatically tested with Xpert MTB\/XDR and bedaquiline and linezolid phenotypic (p)DST in the same episode for diagnosis or treatment monitoring. Data from respiratory specimens collected 01\/01\/2023-31\/12\/2024 across six districts in Western Cape, South Africa, were included.\n                  <bold>Findings:<\/bold>\n                  89% (2799\/3138) of people were successfully tested with Xpert MTB\/XDR, with 12% (332\/2799) fluoroquinolone-resistant. 77% (2423\/3138) successfully underwent bedaquiline pDST, with 12% (278\/2423) resistant. 84% (232\/278) of bedaquiline resistance was in the diagnostic (first) isolate. Of these, 51% (118\/232) had no prior DR-TB (45 prior drug-susceptible TB, 73 no prior TB). We did not identify associations with bedaquiline-resistance, other than residence in Cape Town (OR 1.61, 1.19\u20132.20) and resistance to other drugs (fluoroquinolone resistance the strongest; OR 4.38, 3.20\u20135.96). In people initially bedaquiline-susceptible with a later isolate tested, 22% (45\/201) gained resistance. Bedaquiline-resistance was most frequent in the Overberg region [14% (8, 23) of RR\/MDR-TB]. 86% (2411\/2799) of people had a successful linezolid pDST, with &lt;1% (2\/2411) resistant. All 128 people with repeat linezolid pDST remained susceptible.\n                  <bold>Conclusion:<\/bold>\n                  About one in ten people with RR\/MDR-TB had bedaquiline-resistance, with half due to primary transmission. One in five people with RR\/MDR-TB did not have bedaquiline DST done, highlighting care cascade gaps. Despite long treatment and sustained culture positivity, minimal linezolid resistance occurred.\n                <\/p>","DOI":"10.21203\/rs.3.rs-9144949\/v1","type":"posted-content","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:11:27Z","timestamp":1773817887000},"source":"Crossref","is-referenced-by-count":1,"title":["Bedaquiline and linezolid resistance in people with rifampicin-resistant tuberculosis in the Western Cape Province of South Africa"],"prefix":"10.21203","author":[{"given":"Erick","family":"Auma","sequence":"first","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonas","family":"Ghebrekristos","sequence":"additional","affiliation":[{"name":"National Health Laboratory Service, Greenpoint Tuberculosis Laboratory, Cape Town, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greshan","family":"Kisten","sequence":"additional","affiliation":[{"name":"National Health Laboratory Service, Greenpoint Tuberculosis Laboratory, Cape Town, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiana","family":"Schwab","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarishna","family":"Singh","sequence":"additional","affiliation":[{"name":"National Health Laboratory Service, Greenpoint Tuberculosis Laboratory, Cape Town, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffel","family":"Opperman","sequence":"additional","affiliation":[{"name":"National Health Laboratory Service, Greenpoint Tuberculosis Laboratory, Cape Town, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janre","family":"Steyn","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitta","family":"Derendinger","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabila","family":"Ismail","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouxjeane","family":"Venter","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Warren","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Theron","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization (2022) Implementing the end TB strategy: the essentials, 2022 update. In: WHO, editor. Geneva"},{"key":"ref2","unstructured":"World Health Organization (2022) WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment, 2022 Update"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.7196\/SAMJ.7263","article-title":"Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis","volume":"104","author":"Conradie F","year":"2014","unstructured":"Conradie F, Meintjes G, Hughes J et al (2014) Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis. S Afr Med J 104(3):164\u2013166","journal-title":"S Afr Med J"},{"key":"ref4","article-title":"Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial","author":"Cevik M","year":"2024","unstructured":"Cevik M, Thompson LC, Upton C et al (2024) Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12879-025-11067-2","article-title":"Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"25","author":"Hu X","year":"2025","unstructured":"Hu X, Wu Z, Lei J, Zhu Y, Gao J (2025) Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 25(1):689","journal-title":"BMC Infect Dis"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","article-title":"Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study","volume":"4","author":"Derendinger B","year":"2023","unstructured":"Derendinger B, Dippenaar A, de Vos M et al (2023) Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study. Lancet Microbe 4(12):e972\u2013e82","journal-title":"Lancet Microbe"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1473-3099(21)00470-9","article-title":"Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study","volume":"22","author":"Ismail NA","year":"2022","unstructured":"Ismail NA, Omar SV, Moultrie H et al (2022) Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis 22(4):496\u2013506","journal-title":"Lancet Infect Dis"},{"key":"ref8","unstructured":"Department of Health South Africa (2024) TB Symposium on BPaL-L & The Emergence of Bedaquiline Resistance. In: Department of Health South Africa, editor.: Department of Health South Africa"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/jac\/dkz206","article-title":"Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa","volume":"74","author":"Wasserman S","year":"2019","unstructured":"Wasserman S, Louw G, Ramangoaela L et al (2019) Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa. J Antimicrob Chemother 74(8):2377\u20132384","journal-title":"J Antimicrob Chemother"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(25)00218-X","article-title":"Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study","author":"Mdlenyani L","year":"2025","unstructured":"Mdlenyani L, Mohamed Z, Stadler JAM et al (2025) Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study. Lancet Infect Dis","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00639-2023","article-title":"Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"62","author":"Perumal R","year":"2023","unstructured":"Perumal R, Bionghi N, Nimmo C et al (2023) Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis. Eur Respir J ; 62(6)","journal-title":"Eur Respir J"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2666-5247(20)30031-8","article-title":"Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis","volume":"1","author":"Nimmo C","year":"2020","unstructured":"Nimmo C, Millard J, van Dorp L et al (2020) Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe 1(4):e165\u2013e74","journal-title":"Lancet Microbe"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"10844","DOI":"10.1038\/s41598-022-14581-4","article-title":"Spatial heterogeneity of extensively drug resistant-tuberculosis in Western Cape Province, South Africa","volume":"12","author":"Sy KTL","year":"2022","unstructured":"Sy KTL, Leavitt SV, de Vos M et al (2022) Spatial heterogeneity of extensively drug resistant-tuberculosis in Western Cape Province, South Africa. Sci Rep 12(1):10844","journal-title":"Sci Rep"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"e1002638","DOI":"10.1371\/journal.pmed.1002638","article-title":"Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis","volume":"15","author":"McIntosh AI","year":"2018","unstructured":"McIntosh AI, Jenkins HE, White LF et al (2018) Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis. PLoS Med 15(8):e1002638","journal-title":"PLoS Med"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"e2314813121","DOI":"10.1073\/pnas.2314813121","article-title":"Aerosolization of viable Mycobacterium tuberculosis bacilli by tuberculosis clinic attendees independent of sputum-Xpert Ultra status","volume":"121","author":"Patterson B","year":"2024","unstructured":"Patterson B, Dinkele R, Gessner S et al (2024) Aerosolization of viable Mycobacterium tuberculosis bacilli by tuberculosis clinic attendees independent of sputum-Xpert Ultra status. Proc Natl Acad Sci U S A 121(12):e2314813121","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"102791","DOI":"10.1016\/j.jiph.2025.102791","article-title":"Prominence of Mycobacterium tuberculosis biomarkers among sputum culture-negative clinic attendees, independent of Ultra status","volume":"18","author":"Xie YL","year":"2025","unstructured":"Xie YL, Modi N, Lopez K et al (2025) Prominence of Mycobacterium tuberculosis biomarkers among sputum culture-negative clinic attendees, independent of Ultra status. J Infect Public Health 18(7):102791","journal-title":"J Infect Public Health"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"e0002283","DOI":"10.1371\/journal.pgph.0002283","article-title":"Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid","volume":"3","author":"Timm J","year":"2023","unstructured":"Timm J, Bateson A, Solanki P et al (2023) Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid. PLOS Glob Public Health 3(10):e0002283","journal-title":"PLOS Glob Public Health"},{"key":"ref18","article-title":"High rates of acquired resistance to fluoroquinolones, bedaquiline and linezolid in patients failing treatment against drug-resistant tuberculosis in the Republic of Moldova","author":"Chesov D","year":"2025","unstructured":"Chesov D, Reimann M, Mukherjee T et al (2025) High rates of acquired resistance to fluoroquinolones, bedaquiline and linezolid in patients failing treatment against drug-resistant tuberculosis in the Republic of Moldova. Clin Microbiol Infect","journal-title":"Clin Microbiol Infect"},{"key":"ref19","article-title":"Diagnostic Accuracy of LiquidArray MTB-XDR VER 1.0 for the Detection of Mycobacterium tuberculosis Complex, Fluoroquinolone, Amikacin, Ethambutol, and Linezolid Susceptibility","author":"Auma E","year":"2024","unstructured":"Auma E, Alberts R, Derendinger B et al (2024) Diagnostic Accuracy of LiquidArray MTB-XDR VER 1.0 for the Detection of Mycobacterium tuberculosis Complex, Fluoroquinolone, Amikacin, Ethambutol, and Linezolid Susceptibility. Clin Infect Dis","journal-title":"Clin Infect Dis"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9144949\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9144949\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:12:10Z","timestamp":1773817930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9144949\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":19,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9144949\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,3,18]]},"subtype":"preprint"}}